title: Are reverse payments and pay-for-delay settlements business as usual or an anticompetitive practice?
authors.affiliation: MCPHS University, Worcester, Massachusetts, USA.
authors.forename: Swati
authors.initials: S
authors.lastname: Shah
authors.affiliation: MCPHS University, Worcester, Massachusetts, USA.
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Silva
authors.affiliation: MCPHS University, Worcester, Massachusetts, USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Malloy
mesh_terms: D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence*; D004465:Economic Competition / Q000191:economics* / Q000331:legislation & jurisprudence*; D007880:Legislation, Drug / Q000191:economics*; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D014481:United States; D014485:United States Federal Trade Commission / Q000331:legislation & jurisprudence